境外上市

Search documents
万辰集团: 第四届董事会第三十一次会议决议公告
Zheng Quan Zhi Xing· 2025-08-22 16:36
Group 1 - The company held its 31st meeting of the 4th Board of Directors on August 22, 2025, to discuss various governance matters [1] - The Board approved amendments to the company's Articles of Association and related rules to enhance corporate governance and compliance with legal requirements [2][3] - The Board agreed to seek shareholder approval for the issuance of H shares and listing on the Hong Kong Stock Exchange to further the company's international strategy [3][4] Group 2 - The proposed H share issuance will involve a maximum of 15% of the company's total share capital post-issuance, with an option for overallotment [6] - The issuance will be conducted through a public offering in Hong Kong and an international placement, with specific allocation strategies based on market conditions [5][7] - The company plans to use the proceeds from the H share issuance for network expansion, product development, brand building, and other strategic initiatives [9][10] Group 3 - The Board approved a plan for the company to transition into an overseas fundraising company following the successful issuance and listing of H shares [9][10] - The company will revise its internal governance documents to align with the new structure and regulatory requirements post-listing [18][24] - The Board proposed to establish a confidentiality and archival management system related to the overseas issuance and listing [27]
科兴制药筹划在香港联交所上市
Bei Jing Shang Bao· 2025-08-22 14:04
Core Viewpoint - The company, Sinovac Biotech (688136), is planning to issue overseas listed shares (H shares) and list on the Hong Kong Stock Exchange to enhance its international business development and brand image while optimizing its capital structure and diversifying financing channels [1]. Group 1 - The company aims to deepen its "innovation + internationalization" strategic layout [1]. - The initiative is intended to accelerate the development of overseas business and improve the company's overall competitiveness [1]. - The company is currently in discussions with relevant intermediaries regarding the specific progress of the H share listing, with details yet to be finalized [1].
科兴制药(688136.SH):拟筹划H股上市
Ge Long Hui A P P· 2025-08-22 13:50
格隆汇8月22日丨科兴制药(688136.SH)公布,公司为加快海外业务发展,进一步提高公司综合竞争力及 国际品牌形象,同时充分借助国际资本市场的资源与机制优势,优化资本结构,拓宽多元融资渠道,公 司正在筹划发行境外上市股份(H 股)并在香港联合交易所有限公司上市(以下简称"本次 H 股上市")。公 司正与相关中介机构就本次H股上市的具体推进工作进行商讨,相关细节尚未确定。 ...
利欧股份筹划港股上市有无忽悠成分?实控人遭立案调查!
Xin Lang Cai Jing· 2025-08-22 12:39
Group 1 - The stock price of Liou Co., Ltd. experienced significant fluctuations, with a cumulative increase of over 20% in three consecutive trading days, triggering stock price anomaly regulations [2] - Liou Co., Ltd. is planning to issue shares overseas (H-shares) and list on the Hong Kong Stock Exchange, aiming to enhance its international brand image and financing capabilities [2] - The company's main business is weak, relying heavily on investment income, and its actual controller is under regulatory investigation, raising concerns about the legitimacy of the planned Hong Kong listing [2][6] Group 2 - Liou Co., Ltd. has maintained revenue above 20 billion RMB for several years, with its largest business segment being media agency services, but its growth has stagnated compared to competitors [3][4] - In 2024, Liou Co., Ltd. held a market share of approximately 3% in the media agency sector, significantly trailing behind the leading company, which had a market share of 24% [3][4] - The company has announced plans to use up to 3 billion RMB of its own funds for diversified securities investments, indicating a focus on stock market activities [6] Group 3 - The actual controller of Liou Co., Ltd. is under investigation for suspected insider trading, which may pose challenges for the company's planned overseas listing [6][7] - The investigation involves transactions made by the controller's family member, which have been classified as short-term trading, resulting in a loss [6] - The company asserts that the investigation does not affect its operations and that it will comply with regulatory requirements during this period [7] Group 4 - Liou Co., Ltd. has shown concerning financial metrics, with gross profits fluctuating between 1.3 billion to 1.9 billion RMB, leading to questions about the stability of its business model [8] - The company has reported negative cash flow for four consecutive years from 2021 to 2024, raising doubts about the authenticity of its reported profits [9] Group 5 - Liou Co., Ltd. has engaged in significant related-party transactions, including a recent agreement with a company controlled by its actual controller for construction and engineering services [12][13] - The company claims that these transactions are conducted at market prices and do not harm the interests of the company or its shareholders [13]
科兴制药:筹划在香港联合交易所有限公司上市
Guo Ji Jin Rong Bao· 2025-08-22 10:55
科兴制药公告,公司正在筹划发行境外上市股份(H股)并在香港联合交易所有限公司上市。此举旨在深 化"创新+国际化"战略,加快海外业务发展,提高综合竞争力及国际品牌形象,优化资本结构,拓宽融 资渠道。相关细节尚未确定,需提交公司董事会和股东大会审议,并取得相关政府机构、监管机构备 案、批准或核准。本次H股上市能否通过审议、备案和审核程序并最终实施具有不确定性。 ...
华勤技术筹划发行H股股票并在香港联交所上市
Zhi Tong Cai Jing· 2025-08-22 10:31
华勤技术(603296)(603296.SH)发布公告,为加快公司的国际化战略及海外业务发展,增强公司的境 外融资能力,进一步提高公司的综合竞争力,根据公司总体发展战略及运营需要,公司拟发行境外上市 股份(H股)并在香港联合交易所有限公司(以下简称"香港联交所")主板上市。 ...
华勤技术:筹划发行H股股票并在香港联合交易所有限公司上市
Mei Ri Jing Ji Xin Wen· 2025-08-22 08:57
Group 1 - The company, Huqin Technology, announced plans to accelerate its international strategy and overseas business development by issuing overseas listed shares (H-shares) and listing on the Hong Kong Stock Exchange [1] - The objective of this move is to enhance the company's overseas financing capabilities and improve its overall competitiveness [1] - The company is currently in discussions with relevant intermediaries, and specific details of the plan have not yet been finalized [1]
华勤技术:拟发行境外上市股份并在香港联交所上市
Xin Lang Cai Jing· 2025-08-22 08:57
华勤技术公告,2025年 8月 22日,公司召开了董事会和监事会,审议通过了发行境外上市股份(H 股) 并在香港联交所主板上市的相关议案。此举旨在加快公司国际化战略,增强境外融资能力,提高综合竞 争力。具体细节尚未最终确定,需提交股东大会审议,并取得中国证监会、香港联交所和香港证券及期 货事务监察委员会等相关机构的备案、批准和核准。目前,公司正与中介机构商讨发行事宜,但发行能 否成功存在重大不确定性。 ...
利欧股份筹划港股上市有无忽悠成分?实控人遭立案调查 关联交易助力资本运作?
Xin Lang Zheng Quan· 2025-08-22 04:37
Core Viewpoint - Lio Co., Ltd. is facing challenges with weak core business performance and negative cash flow, raising concerns about the quality of its earnings. Additionally, the actual controller of Lio Co., Ltd. is under regulatory investigation, leading to questions about the legitimacy of its planned Hong Kong listing [1][9]. Group 1: Business Performance - Lio Co., Ltd. has a weak core business, primarily relying on investment activities for profitability. The company has been involved in numerous acquisitions, spending over 5 billion yuan on acquiring stakes in more than 20 companies [1]. - The company has two main business segments: mechanical manufacturing and digital marketing. However, its revenue growth has stagnated, with a market share of approximately 3% in the media agency sector, significantly trailing behind the leading competitor, which has a revenue of 20.64 billion yuan [2][3]. - Despite appearing to have substantial revenue, the actual profitability is concerning, with gross profits fluctuating between 1.3 billion yuan and 1.9 billion yuan, leading to a net profit margin of only 200 million to 400 million yuan after accounting for expenses [5][6]. Group 2: Cash Flow and Investment Activities - The company has reported negative cash flow for four consecutive years from 2021 to 2024, raising doubts about the authenticity of its earnings [6]. - Lio Co., Ltd. has shown a keen interest in stock market investments, with plans to use up to 3 billion yuan of its own funds for various securities investments, including new stock subscriptions and bond investments [8]. Group 3: Regulatory Issues - The actual controller of Lio Co., Ltd., Wang Xiangrong, and Vice Chairman Wang Zhuangli are under investigation by the China Securities Regulatory Commission for suspected short-term trading activities involving their mother [9][10]. - The ongoing investigation may pose obstacles to the company's planned overseas listing, as regulatory guidelines prohibit companies with recent legal issues from issuing securities abroad [10]. Group 4: Related Party Transactions - In light of the financial pressures faced by *ST Chuangxing, Lio Co., Ltd. has engaged in related party transactions, raising concerns about potential conflicts of interest and the risk of being financially drained [11][14]. - The company has signed a framework agreement with a related party for construction and engineering services, which it claims will be conducted at fair market prices and will not harm the interests of the company or its shareholders [14].
锐明技术: 半年报董事会决议公告
Zheng Quan Zhi Xing· 2025-08-21 12:18
Group 1 - The company held its 14th meeting of the 4th Board of Directors on August 20, 2025, with all 7 directors present, confirming the legality and validity of the meeting [1] - The Board approved the 2025 semi-annual report, affirming that it accurately reflects the company's operational status without any misleading statements [1][2] - The profit distribution plan for the first half of 2025 was approved, proposing a cash dividend of 4 yuan per 10 shares, with no capital reserve conversion or bonus shares [2] Group 2 - The company plans to issue H shares and apply for listing on the Hong Kong Stock Exchange to enhance its global strategy and competitiveness [8][9] - The issuance will be conducted through public offerings in Hong Kong and international placements, with a maximum of 15% of the total share capital to be issued [10][11] - The company will use the funds raised for technology development, international manufacturing, market branding, and general corporate purposes [17][18] Group 3 - The Board has proposed to eliminate the supervisory board, transferring its responsibilities to the audit committee, and will amend the company’s articles of association accordingly [4][6] - The company will appoint new senior management, including two deputy managers, with their terms lasting until the end of the current Board's tenure [6][7] - The company will also change its accounting firm, not renewing the contract with the current auditor, and will seek approval from the shareholders [6][7]